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Most cases of neurodegenerative diseases are spo-
radic, hindering the use of genetic mouse models
to analyze disease mechanisms. Focusing on the
motor neuron (MN) disease amyotrophic lateral scle-
rosis (ALS), we therefore devised a fully humanized
coculture model composed of human adult primary
sporadic ALS (sALS) astrocytes and human embry-
onic stem-cell-derived MNs. The model reproduces
the cardinal features of human ALS: sALS astrocytes,
but not those from control patients, trigger selective
death of MNs. The mechanisms underlying this non-
cell-autonomous toxicity were investigated in both
astrocytes and MNs. Although causal in familial
ALS (fALS), SOD1 does not contribute to the toxicity
of sALS astrocytes. Death of MNs triggered by either
sALS or fALS astrocytes occurs through necroptosis,
a form of programmed necrosis involving receptor-
interacting protein 1 and the mixed lineage kinase
domain-like protein. The necroptotic pathway there-
fore constitutes a potential therapeutic target for
this incurable disease.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an incurable, adult-onset
paralytic disorder that presents mainly as a sporadic condition
(sALS), i.e., it occurs in absence of any evidence of family history.
Mutations in superoxide dismutase-1 (SOD1) cause a rare form
of familial ALS (fALS), and transgenic rodents expressing mutant
human SOD1 (mutSOD1) capture many of the hallmarks of this
fatal neurodegenerative disease, including the characteristicloss of motor neurons (MNs) (Kanning et al., 2010). Most of our
current knowledge about the mechanisms of MN degeneration
in ALS originates from studies in these fALS mouse models.
One clear conclusion from these studies is that nonneuronal
cells play a critical role in mutSOD1-related neurodegeneration
(Ilieva et al., 2009). We and others (Cassina et al., 2005; Di Gior-
gio et al., 2007; Nagai et al., 2007) have shown that astrocytes
can provoke spontaneous degeneration of MNs. In particular,
mutSOD1mouse astrocytes trigger the death of both mouse pri-
mary and mouse embryonic stem-cell-derived MNs (mES-MNs),
regardless of whether or not these neurons express pathogenic
SOD1 mutations (Nagai et al., 2007). Accordingly, mouse mut-
SOD1-expressing glial-restricted precursors grafted into spinal
cords of wild-type (WT) rats produce a loss of neighboring
MNs (Papadeas et al., 2011). These in vitro and in vivo studies
demonstrate that mutSOD1-expressing astrocytes, but not
other cell types, can induce MN degeneration. However, all of
these findings were generated using cells from the mutSOD1
mouse. This is a potential issue both because levels of mutSOD1
are 6-fold higher than those of the endogenous protein, and
because of the uncertainty about what degree insights into
human disease can be gained from murine models.
Subsequent studies have addressed some but not all of these
concerns. Di Giorgio et al. (2008) and Marchetto et al. (2008)
showed that both mouse mutSOD1-expressing astrocytes and
human fetal astrocytes transduced to overexpress SOD1 muta-
tions cause loss of human ES-MNs (hES-MNs). Haidet-Phillips
et al. (2011) reported that neural progenitor cell (NPC)-derived
astrocytes generated postmortem from both sporadic and
fALSSOD1 patients were toxic for mES-MNs when cocultured,
whereas NPC-astrocytes from a single non-ALS control were
not toxic. However, it remains to be determined whether a
non-cell-autonomous death phenotype would be observed in a
fully humanized model of ALS.
The nature of the toxic activitymediated by astrocytes, and the
mechanisms of MN death that they trigger, remain unclear evenNeuron 81, 1001–1008, March 5, 2014 ª2014 Elsevier Inc. 1001
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potential to reveal new therapeutic targets. One candidate toxic
factor in sALS was SOD1 itself, given that misfolded wtSOD1 is
enriched in MNs of some sALS patients (Bosco et al., 2010;
Guareschi et al., 2012). In keeping with this possibility, Haidet-
Phillips et al. (2011) reported that silencing SOD1 in hNPC-astro-
cytes from sALS patients (hence without SOD1 mutations) did
attenuate the loss of mES-MNs.
Here, we have succeeded in creating a fully humanized in vitro
model of ALS and show that astrocytes from sALS patients
specifically kill hES-MNs, whereas control astrocytes do not.
However, contrary to Haidet-Phillips et al. (2011), we show
that silencing SOD1 in human astrocytes from sALS patients
(henceforth referred to as sALS astrocytes) does not mitigate
MN toxicity. Instead, we found that MNs die in both the mouse
mutSOD1 and the human sALS in vitro models by a caspase-
independent form of programmed cell death (PCD) with necrotic
morphology that closely resembles necroptosis, a form of pro-
grammed necrosis (Ofengeim and Yuan, 2013). Inhibition of
this unique mechanism of non-cell-autonomous MN death
represents a potential avenue for therapeutic investigations.
RESULTS
To closely model the human disease, we generated human adult
astrocytes from sALS patients. Tissue samples were collected
from motor cortex and, whenever possible, spinal cord within
11 hr of the time of death. The age-matched donors included
six sALS patients (i.e., no family history of ALS or a mutation in
any of the 27 familial ALS genes [see Supplemental Experimental
Procedures available online]), 12 nonneurological controls
comprising six nondisease controls (NDC) and six controls
who died from respiratory failure due to chronic obstructive res-
piratory disorder (COPD), and three neurological controls with
Alzheimer’s disease (AD) (Figure S1A).
One day after plating, the human CNS cultures were com-
posed predominantly of astrocytes and/or astrocyte precursors,
as evidenced by 90% of the cells being CD44+, 70%
vimentin+, and 60% glial fibrillary acidic protein (GFAP)+ (Fig-
ure S1B). By 7 days postplating, the proportions of GFAP+ and
vimentin+ cells were essentially similar to those of the CD44+
cells (Figure S1B). Conversely, the NPC markers SOX2 and
PAX6 were not detected in three out of the four CNS cultures
tested. In the one positive case, SOX2+/PAX6+ cells were
observed only at 1 and 3 days postplating, and 95% of those
cells were CD44+ and/or GFAP+. Collectively, our data argue
against the possibility that NPCs are major contributors to our
human astrocyte cultures in contrast to those of Haidet-Phillips
et al. (2011).
After 1 month postplating, the human CNS cultures became
confluent, and cells maintained their CD44, vimentin, and
GFAP expression patterns and displayed a star-like appearance
with several fine processes (Figures 1A and S1C). These features
were observed both in the NDC and the patient-derived COPD,
AD, and sALS astrocytic cultures. In addition, other astrocyte
markers as well as markers of immaturity/maturity and of
reactivity did not differ among the four culture types or were
not detected (Figure S1D). Furthermore, among a panel of1002 Neuron 81, 1001–1008, March 5, 2014 ª2014 Elsevier Inc.31 chemokines/cytokines, only a few were detected in the astro-
cyte culture media and, of these, only monocyte chemoattrac-
tant protein 1 (MCP1; gene CCL2) differed among the four
groups (Figure S1D). As for other cellular components in the
cultures, immunocytochemistry revealed no oligodendrocytes
(20,30-cyclic-nucleotide 30-phosphodiesterase [CNPase]), neu-
rons (microtubule associated protein 2 [MAP2]), or microglia
(ionized calcium binding adaptor molecule 1 [Iba1]) (Figure S1C).
Likewise, quantitative RT-PCR (qRT-PCR) analysis indicated the
absence of markers of oligodendocytes (myelin-associated
glycoprotein [MAG]), neurons (synaptosomal-associated protein
25 [SNAP25]), microglia (Iba1), and endothelial cells (endothelial
nitric oxide synthase [eNOS]) in all four groups of human CNS
cultures.
To produce human spinal MNs, we differentiated the HUES3
Hb9::GFP reporter cell line (Di Giorgio et al., 2008), which ex-
pressesGFP under the control of theMN-specificHb9 promoter,
using a protocol of early neuralization, retinoic acid caudaliza-
tion, and sonic hedgehog agonist ventralization (Amoroso
et al., 2013). Using this protocol, 20%–30% of the hES-derived
neurons were GFP+ MNs (Figure 1B). We confirmed that, like
mES-MNs, hES-MNs were also susceptible, and to a similar de-
gree (i.e.,50% reduction in GFP+MNs at 7 days), to the toxicity
of mouse mutSOD1 astrocytes (data not shown).
This result encouraged us to test the effects of sALS astro-
cytes on hES-MNs (Figures 1B–1F). Over a period of 14 days,
the numbers of hES-MNs cultured on sALS astrocyte layers,
but not those cultured on COPD and AD astrocytes, decreased
substantially more than did those cultured on NDC astrocytes,
reaching a plateau at day 7 (Figure 1G). Of note, at day 7 the dif-
ference in the numbers of GFP+ neurons cultured on sALS versus
control astrocytes was comparable to that of neurons immuno-
stained for the MN marker nonphosphorylated neurofilament
heavy chain (SMI32) or that of large neurons transduced with a
viral vector expressing a CMV::RFP-reporter (Figure S1E). We
thus conclude that the reduction in GFP+ MN numbers reflect
an actual loss of cells and not merely a loss of GFP expression.
To be considered predictive, any in vitro model of ALS needs
to reproduce a cardinal feature of ALS, namely, selectivity for
MNs. Survival at day 7 of non-MNs in mixed hES-derived cul-
tures—as evidenced by counting both MAP2+/GFP non-MNs
and GABA+/MAP2+ GABAergic interneurons—was not dimin-
ished by sALS as compared to control astrocytes (Figure 1H).
Lastly, unlike astrocytes, primary fibroblasts from sALS patients
did not cause any detectable reduction in hES-MNs compared
to controls (Figure 1I). Non-cell-autonomous toxicity is there-
fore selective for MN-astrocyte interactions in human as in
mouse.
Given the proposed roles for misfolded wtSOD1 as a cytotoxic
factor even in sALS, we next explored the potential contribution
of wtSOD1 to the toxicity of sALS astrocytes. Four lentiviral vec-
tors, each expressing a different shRNA to human SOD1, were
first tested in cells from our mutSOD1 mice, which express the
G93A mutation found in human fALS patients. In infected and
puromycin-selected primary mutSOD1 astrocytes, the shRNAs
reduced SOD1 mRNA and protein by 50% to >75% (Figures
S2B and S2C) and mitigated the toxicity of these astrocytes to
mES-MNs (Figures 2A–2E).
Figure 1. Primary Sporadic ALS Astrocytes Specifically Kill Human
ES-MNs
(A) GFAP and vimentin immunostaining of primary astrocyte monolayers
(astro) from sALS patients. (B) GFP and MAP2 immunostaining of hES-MN.
(C–F) Representative images of hES-MNs cultured for 7 days on astro pro-
duced fromNDC (C), COPD (D), AD (E), or sALS (F) subjects.White arrowheads
indicate GFP+/MAP2+ MNs. (G) Quantification of hES-MN numbers over
14 days on NDC, COPD, AD, or sALS astro. Extra-sum-of-squares ANOVA
(Bates and Watts, 1988) indicates that NDC, COPD, and AD curves do not
differ (F[3,33] < 2.44; p > 0.075) but that these curves are different from the sALS
curve (F[3,33] > 19.12, p < 0.001). (H) The number of GFP
+/MAP2+ MNs is
reduced when cocultured for 7 days with sALS astro compared to Ctrs astro
(Ctrs = NDC, and/or COPD and/or AD) (t[1,4] = 5.53 1014, p = 1.00), but the
number of non-MN neurons (MAP2+/GFP or GABA+/MAP2+) does not differ
between the two conditions (t[4] = 0.523, p = 0.63). (I) The number of hES-
MNs is not different between cocultures with NDC or sALS fibroblasts after
7 days (t[16] = 0.023, p = 0.98). Values represent means ± SEM (n = 3–9 per
group). p values in (H) and (I) are from two-tailed unpaired Student’s t tests.
Scale bars represent 20 mm in (A) and (B) and 40 mm in (C)–(F).
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sALS astrocytes that carried no SOD1 mutation. Knockdown of
SOD1 mRNA in human cells with these four viral vectors was as
effective or even more effective (clone 39808) as in mouse cells
(Figures S2B and S2C), and the magnitude of reduction in
SOD1 protein in human cells was more consistent across the
four hairpins than in mouse cells (Figures S2B and S2C). Strik-
ingly, however, the loss of hES-MNs caused by sALS astrocytes
was not attenuated bySOD1 silencing, regardless of whether the
data were analyzed by individual shRNAs (Figures 2F–2J) or by
individual patients (Figure S2D). Finally, silencing TAR DNA-
binding protein 43 (TDP-43) in sALS astrocytes by 70%–80%
(Figure S2D) also failed to mitigate hES-MN degeneration (Fig-
ure S2E). Thus, our results indicate that neither SOD1 nor TDP-
43 contribute to sALS astrocyte toxicity.
To determine whether the mechanism by which sALS astro-
cytes are toxic to hES-MNs may be similar to that observed in
the mouse mutSOD1 model (Nagai et al., 2007), we performed
three experiments. First, in cocultures of sALS astrocytes with
primary mouse spinal cord neuronal cultures, we found fewer
mouseGFP+-MNs (55%± 6%), but no difference inMAP2+GFP
non-MNs, 7 days after plating, compared to cocultures with con-
trol astrocytes (Figure 3A). Second, medium conditioned for
7 days with human sALS astrocytes phenocopied the selective
toxicity of sALS astrocyte cells themselves to hES-MNs (Fig-
ure 3B). Finally, at day 3 in culture, a time point at which the
number of hES-MNs is still 85% of control, the proportions of
hES-MNs displaying signs of DNA fragmentation (TUNEL assay),
caspase-3 activation (fractin immunocytochemistry), or loss of
plasma membrane integrity (ethidium homodimer [EthD] assay)
were 2- to 4-fold higher in cocultures with sALS astrocytes as
compared to control astrocytes (Figure 3C). These results are
in keeping with those made previously in the mutSOD1 model
(Nagai et al., 2007), and thus, both human sALS and mouse
mutSOD1 astrocytes kill MNs probably via a soluble toxic factor
that triggers a form of PCD with features of necrosis.
We sought to characterize further themode of astrocyte-medi-
ated MN death by performing, whenever possible, parallel
studies in mouse and humanMNs and with genetic and pharma-
cological interventions (Figure S3A). Given the critical role playedNeuron 81, 1001–1008, March 5, 2014 ª2014 Elsevier Inc. 1003
Figure 2. SOD1 Knockdown inMouse, but Not in Human Astrocytes,
Mitigates MN Loss
(A–D) Representative images of GFP+ mES-MNs cultured for 7 days on mouse
nontransgenic (NTg) astro infected with lentiviral empty vector (EV) (A)
or a lentiviral shRNA hairpin (B) to knockdown human SOD1 (clone
TRCN0000039812, 39812) or transgenic SOD1G93A (fALS) astro infected with
lentiviral EV (C) or lentiviral SOD1 shRNA 39812 (D). (E) Quantification of GFP+
mES-MN number after 7 days on NTg or fALS astro infected with EV or one of
the four shRNA clones against human SOD1 (39812, 18344, 39808, or 9869).
GFP+ mES-MN numbers on the fALS/EV astro are lower than on NTg/EV astro
(*p < 0.001). However, GFP+mES-MN numbers on the fALS/shSOD1 astro are
not different than those on the NTg/shSOD1 astro (p > 0.05). (F–I) Represen-
tative images of GFP+ hES-MNs cultured for 7 days on astro prepared from
NDCor sALS subjects. NDC astro were infectedwith EV (F) or the shRNA clone
39812 (G). sALS astro were also infected with EV (H) or clone 39182 (I). (J)
Quantification of GFP+ hES-MN number after 7 days on Ctrs or sALS astro
infected with EV or one of the four shRNA clones. GFP+ hES-MN numbers are
lower when cocultured with sALS astro as compared to NDC astro under all
lentiviral conditions (EV and shSOD1) (*p < 0.001). In addition, when compared
within Ctrs or sALS conditions, GFP+ hES-MN numbers are not different
between EV- and shRNA-infected astro. (E and J) Data are expressed as
percent of MN number on NTg or NDC astro infected with EV (percentage of
NTg/EV or of NDC/EV) and represent means ± SEM (n = 3–9). p values in (E)
and (J) are from post-ANOVA Newman-Keuls tests. (A–D and F–I) White ar-
rowheads indicate GFP+ MNs. Scale bars represent 40 mm.
Neuron
Motor Neuron Necroptosis in Sporadic and SOD1 ALS
1004 Neuron 81, 1001–1008, March 5, 2014 ª2014 Elsevier Inc.by the Bcl-2 family in apoptosis, we first targeted the procell
death protein Bax (Figure 3D). Bax/ primary mouse MNs
were resistant to mutSOD1 astrocyte toxicity (Figure S3B) and
the pentapeptide Bax inhibitor V5 completely protected hES-
MNs exposed to sALS astrocytes (Figure 3D). This effect was
specific to Bax: neither Bak- nor Bim-deleted mouse primary
MNs were more resistant to mutSOD1 astrocytes than their
WT counterparts (Figure S3B). Moreover, inhibition of p53 by pi-
fithrin-a or pifithrin-m conferred no protection in either mouse or
human systems (Figures S3C and S3D).
Caspases are the classical downstream effectors of Bax in the
apoptotic pathway. However, although zVAD-fmk eliminated
caspase-3 activation detected by fractin labeling in hES-MNs
exposed to sALS astrocytes (Figure S3E), it did not increase
the number of surviving MNs (Figure 3D), as we previously
showed in mouse (Nagai et al., 2007). Moreover, zVAD-fmk did
not reduce the fraction of EthD+ or TUNEL+ MNs in the human
cultures (Figure S3E). Similarly, neither Ac-DNLD-CHO, which
primarily inhibits the executioners caspase-3 and caspase-7,
nor zIETD-fmk, a caspase-8 inhibitor, mitigated the MN loss in
either the mouse (Figure S3C) or human (Figure S3D) coculture
systems. Thus, MN death triggered by either fALS or sALS
astrocytes is Bax dependent but caspase independent.
Necroptosis is a form of programmed necrosis that is not pre-
vented by caspase inhibition (Ofengeim and Yuan, 2013) and is
associated with loss of plasma membrane integrity (see EthD
positivity in Figure 3C). We therefore targeted two key effectors
of necroptosis, receptor-interacting serine/threonine-protein
kinase 1 (RIP1) and mixed lineage kinase domain-like (MLKL)
(Ofengeim and Yuan, 2013), in both mouse and human coculture
systems. The RIP1 antagonist necrostatin-1 (Degterev et al.,
2008) prevented the loss of ES-MNs exposed to either mutSOD1
or sALS (Figure 4A) astrocytes. Necrostatin-1 also reverted the
proportions of EthD+ and TUNEL+ hES-MNs exposed to sALS
astrocytes back to control levels (Figure 4B). In contrast,
Figure 3. Human and Mouse Astrocytes Are Toxic through Similar
Mechanisms
(A) Like hES-MNs (Figure 1H), mouse primary MN number is lower when
cocultured with sALS astro as compared to Ctrs astro after 7 days (left, t[22] =
Neuron
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tion of fractin+ ES-MNs in the human system remained un-
changed (Figure 4B; data not shown for mouse). As an indepen-
dent verification of the role of RIP1, mouse primary MNs were
infected with a lentiviral vector expressing a RIP1 shRNA
(22465) that reduced RIP1 levels in MNs by 90% (Figure S4A).
This knockdown provided nearly complete protection of mouse
MNs exposed to mutSOD1 astrocytes (Figure 4C); comparable
results were obtained with a second shRNA (22468; Figures
S4A and S4B). Likewise, the silencing of RIP1 in hES-MNs by
shRNA (200006; 60% reduction in human RIP1; Figure S4C)
conferred complete protection against human sALS astrocyte
toxicity (Figure 4D). In light of the discovery that MLKL can be
specifically inhibited by necrosulfonamide (NSA) (Sun et al.,
2012), we incubated our human cultures with this small molecule
at a concentration of 0.25 mM. Under these conditions, NSA also
reduced by 90% the toxicity of sALS astrocytes for hES-MNs
(Figure 4E). MN death triggered by toxic astrocytes from both
familial and sporadic sources therefore bears the pharmacolog-
ical hallmarks of necroptosis.
DISCUSSION
We report the development of a fully humanized in vitro model
of sALS and its use to define a mechanism of MN degeneration.
Primary adult astrocytes harvested from postmortem CNS
tissues of sALS patients trigger degeneration of hES-MNs by
the caspase-independent necroptosis pathway. This degenera-
tion reflects many key hallmarks of ALS in vivo in human pa-
tients and mouse models. First, toxicity is only observed with
ALS astrocytes and not with those from a series of other dis-
eases or normal controls; albeit, we did not find any difference
in the proportion of astrocytes or their degree of maturation
among the four culture groups. Second, the toxicity is not
linked to a heightened state of astrocyte reactivity. Third, it
selectively affects MNs as compared to other neuronal classes.
Lastly, another cell type from sALS patients, namely fibroblasts,
does not exert MN toxicity. Using this validated system based
on primary astrocytes, we excluded SOD1 itself as the toxic
factor in sALS astrocytes. In contrast, our demonstration that
the necroptosis pathway is required for astrocyte-triggered
degeneration of MNs in both the human sALS and mouse7.619, *p = 1.32 3 108). In the same coculture wells, the number of non-MN
neurons do not differ between sALS or Ctrs astro (MAP2+/GFP, right, t[17] =
0.892, p = 0.385). (B) hES-MN number is lower when grown in media
conditioned by sALS astrocytes as compared to Ctrs astrocytes (ACM)
(left, *p < 0.001). Non-MN neuron numbers do not differ between these two
conditions (MAP2+/GFP, right, p = 0.626). (C) Numbers of hES-MNs fractin+
(*p = 2.633 104), EthD+ (*p = 1.483 103), or TUNEL+ (*p = 9.113 104) MNs
are higher after 3-day exposure to sALS astro compared to Ctrs astro. (D) The
reduction in hES-MN number when cocultured with sALS astro as compared
to Ctrs astro (DMSO vehicle [Veh], *p < 0.001) is not mitigated by the addition
of the pancaspase inhibitor zVAD-FMK (zVAD, 20 mM, *p < 0.001). Inhibition of
Bax by the pentapeptide V5 (50 mM) abrogates the difference in hES-MN
numbers when cocultured with sALS or Ctrs astro. Data are expressed as
percent of MN or neuron number on Ctrs astro and represent means ± SEM
(n = 4–7 per group). p values in (A) are from two-tailed unpaired Student’s
t tests and in (B)–(D) are from post-ANOVA Newman-Keuls tests.
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Figure 4. ALS Astrocytes Trigger Necroptosis in MNs, in an RIP1/
MLKL-Dependent Manner
(A) Mouse primary or hES-MN MN number is reduced when cocultured for
7 days with fALS or sALS astro as compared to non-ALS astro (NTg, Ctrs) in
the presence of vehicle (DMSO, *p < 0.001, left). The RIP1 inhibitor necrostatin-
1 (Nec1, 5 mM) abrogates the MN loss observed in both mouse and human
cocultures, respectively (p = 0.532, p = 0.829, right). (B) There are fewer
TUNEL+ and EthD+ (*p < 0.001) hES-MNs but not fractin+ (p = 0.182) MNs in
sALS astro cocultures incubated with Nec1 compared to Veh. (C) There are
more mouse primary MNs in cocultures with fALS astro where MNs are
transduced with the viral vector containing the shRNA against RIP1 (22465)
compared to EV or nonmammalian targeted scrambled (SC) transduced MNs
(*p < 0.001). (D) There are more hES-MNs in cocultures with sALS astro where
MNs are transduced with the viral vector containing the shRNA against RIP1
(200006) compared to EV-transduced hES-MNs (*p < 0.001). (E) In presence of
Veh (DMSO), there are fewer (*p < 0.001) MNs on sALS astro compared to Ctrs
astro. The loss of hES-MNs cocultured for 7 days on sALS astro is prevented
by 250 nMof theMLKL inhibitor necrosulfonamide (NSA), as hES-MN numbers
no longer differ (p > 0.123). Data are expressed as percent of MN number on
Ctrs astro (A and E), or NTg astro (A), as percent of total MN population (B), or
as percent of clone-transduced MN number on NTg astro (C and D) and
represent means ± SEM (n = 3–5 per group). p values in (A)–(E) are from post-
ANOVA Newman-Keuls tests.
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strategies.
HowALS astrocytes become toxic remains unclear. No known
ALS-linked mutations were identified in our sALS samples and
yet the toxic phenotype persisted even after several passages
of the cultured adult astrocytes. Similarly, Haidet-Phillips et al.
(2011) found that NPC-astrocytes from a patient with an SOD1
mutation were toxic to MNs even after extensive expansion.
In contrast, we have not found similar toxicity using induced
pluripotent stem cell (iPSC)-derived astrocytes from patients
with SOD1 mutations (C. Henderson, personal communication).
It seems therefore that some as-yet-unknown sALS-related
imprinting in situ induces primary astrocytes to become and
remain toxic. The lack of toxicity of astrocytes from control
patients, and the fact that human sALS astrocytes do not show
increased reactivity, suggests that toxicity does not result from
generalized agonal hypoxia or a generic neuroinflammatory
response. This implies the existence of a specific process
underlying the gain of toxicity by human sALS astrocytes.
Understanding the underlying epigenetic and genetic changes
would shed considerable light on the progressive emergence
of the ALS clinical phenotype.
Using our primary human sALS astrocyte/hES-MN coculture
system, we found no evidence for a role of SOD1 in astrocyte
toxicity. This is in contrast to the report from Haidet-Phillips
et al. (2011) showing that knockdown of wtSOD1 protects
mES-MNs against sALS NPC-astrocytes. How could this
disparity be explained? Since we show that mouse and hES-
MNs are equally susceptible to sALS astrocyte toxicity, the
species origin of the MNs is not likely to explain the discrepancy.
Our viral vectors led to the knockdown of human SOD1 protein
by 50%–75%, comparable to the 50% of protein reduction
described to be effective in Haidet-Phillips et al. (2011), so
differences in the magnitude of silencing also do not explain
the divergent results. The puromycin selection on astrocytes
cannot have masked a beneficial effect of silencing SOD1 in
sALS astrocytes since MN survival did not differ between
Neuron
Motor Neuron Necroptosis in Sporadic and SOD1 ALScocultures with nontreated astrocytes and EV-infected astro-
cytes treated with puromycin (Figure S2A). However, there
were other technical differences. We used four different shRNAs
targeting SOD1, none of which prevented astrocyte toxicity for
MNs. One possibility is that the single shRNA hairpin used by
Haidet-Phillips et al. (2011) caused off-target effects that led to
a reduction in toxicity. Another difference is that our selection
process generated cultures composed only of successfully
transduced astrocytes and we systematically controlled for
astrocyte density to exclude the possibility that a given shRNA
might reduce astrocyte number and thereby affect toxicity indi-
rectly. It is important to stress that our findings about the lack
of SOD1 contribution only pertain to the non-cell-autonomous
arm of ALS pathogenesis. The present study does not conflict
with findings that misfolded wtSOD1 may contribute to MN
degeneration by a cell-autonomous mechanism as proposed in
several publications (Bosco et al., 2010; Guareschi et al., 2012).
Our observation that ES-MN death triggered by astrocytes
was caspase independent and led to loss of plasma membrane
integrity (i.e., EthD labeling) raised the possibility that the pro-
cess was necrotic. These data alone did not exclude the possi-
bility that upon caspase inhibition, MNs shift their form of PCD
from apoptotic to nonapoptotic secondary necrosis (Krysko
et al., 2006). However, we further found that inhibition of the
key necroptosis effector RIP1 or MLKL, which plays a critical
role in allowing the MLKL-RIP1-RIP3 necrosome complex to
interact with downstream effectors (Ofengeim and Yuan,
2013), fully protected against sALS astrocyte-induced ES-MN
death even in the absence of zVAD-fmk. This provided compel-
ling evidence that necroptosis is the dominantmode of cell death
in our in vitromodel of sALS. Necroptosis has already been impli-
cated in acute insults, such as brain ischemia (Degterev et al.
2005), but, to our knowledge, never before in a model of a neuro-
degenerative condition such as ALS. Tumor necrosis factor-a
(TNF-a), Fas ligand (FasL), and TNF-related apoptosis-inducing
ligand (TRAIL) are known to activate necroptosis upon ligation
of their cognate receptors (Ofengeim and Yuan, 2013). However,
none of these three agonists of necroptosis were detected by us
in either mutSOD1 or sALS astrocyte-conditioned media (Nagai
et al., 2007; Figure S1D; see Supplemental Information).
The signaling cascade downstream of RIP1 may provide a
significant array of novel candidate therapeutic targets. The
fact that MN death is dependent on Bax points to mitochondrial
involvement, suggesting three potential mechanisms. Involve-
ment of mitochondrial reactive oxygen species (Zhang et al.,
2009) seems unlikely since neither the scavenger Mn-TBAP nor
N-acetylcysteine protected MNs from mutSOD1-expressing
astrocytes (D.B.R. et al., unpublished data). A second possibility
is that mitochondria drive necroptosis via Bax-dependent per-
meabilization of the mitochondrial outer membrane, leading to
the release of procell death factors such as AIF and subsequent
DNA degradation and PCD (Artus et al., 2010). This might explain
why the robust TUNEL signal that we observed (Figure 1I) was
unexpectedly not reduced by zVAD-fmk. Third, at least in
response to apoptotic signals, Bax can promote mitochondrial
fission (Sheridan et al., 2008), which in turn can drive necroptosis
through activation of dynamin-1-like protein by PGAM5 (Wang
et al., 2012).Our completely humanized cell model of sALS demonstrates
that astrocyte-MN interactions are sufficient to trigger sponta-
neous neurodegeneration with many of the key aspects of the
human disease. Our failure to find evidence of a role for SOD1
in our in vitro sALSmodel calls for a re-evaluation of the rationale
of using therapeutic strategies aimed at reducing SOD1 expres-
sion in ALS patients other than those carrying SOD1 mutations.
However, our data do reveal a mechanism of non-cell-autono-
mous MN death, namely a Bax-sensitive form of necroptosis,
whose inhibition represents a potential avenue for therapeutic
intervention. The pathogenic significance of this molecular death
pathway in ALS will have to be established in future studies by,
for example, targeting RIP1 in in vivo models of the disease.
EXPERIMENTAL PROCEDURES
Only unpublishedmethods are described here; detailedmethods can be found
in the Supplemental Experimental Procedures. All the studies with human
postmortem tissues were approved by Columbia IRB Committee protocol
AAAA8153, ALS COSMOS Multicenter study IRB AAAD9986, and Columbia
Coordinating Center IRB AAAC6618. The work performed with MNs derived
from human embryonic stem cells has been approved by Columbia University
ESCRO committee (Embryonic Stem Cell Research Oversight committee).
Procedures related to in vitro experimentation with cells produced or derived
from mice were approved by Columbia IACUC protocol AAAD8107.
Primary Cultures
Human astrocyte cultures were made as previously described by De Groot
et al. (1997). Autopsied tissues were obtained from Columbia Medical Center
Morgue or the National Disease Research Interchange (NDRI). The skin
biopsies were performed after obtaining informed consent and fibroblasts
were expanded and maintained under standard culture conditions in Medium
106 supplemented with LSGS (Life Technologies).
ES-Derived Neuron Cultures
Human spinal ES-MNs were derived as described previously (Amoroso et al.,
2013).
Gene Silencing in Astrocytes and Motor Neurons
All shRNAs and EV used in this study were from SigmaMISSION. See Supple-
mental Experimental Procedures for details about the different hairpins.
For astrocytes, a suspension of 100,000 cells/ml was treated with 8 mg/ml
of hexadimethrine bromide (Sigma), exposed to lentiviral particles at an
MOI of 15, centrifuged (800 3 g, 30 min, room temperature), and plated
(20,000 cells/well). After 48 hr, cells were selected by 1 mg/ml puromycin for
4.5 days and placed by in normal medium for 7 days before coculture with
MNs. For both primary and ES-derived MNs, hexadimethrine bromide and pu-
romycin were omitted.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2014.01.011.
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